Opioids and Chronic Pain Management
Opioids have an important but limited role in chronic pain management, and long‑term use is linked with a wide range of adverse effects that need careful monitoring. Understanding their history, how “typical” and “atypical” opioids work, and the potential harms (from constipation to opioid‑induced hyperalgesia, hormonal changes, immune effects, and overdose) helps patients make more informed decisions with their clinicians.[1][2][3]
A BRIEF HISTORY OF OPIOIDS IN PAIN CARE
Opioid medicines originate from the opium poppy and have been used for pain relief, sedation, and euphoria for thousands of years. In the 19th and 20th centuries, morphine, codeine, and later synthetic opioids such as oxycodone and fentanyl were developed, allowing more precise medical use but also contributing to dependence and misuse. From the 1980s and 1990s, influential articles and guidelines promoted opioids for chronic non‑cancer pain, leading to a marked rise in prescribing, followed by clear evidence of increased addiction, overdose deaths, and opioid‑related harm, especially in the United States.[4][5][6][1]
Modern guidelines now emphasise cautious, time‑limited, and goal‑directed use of opioids for chronic pain, generally after other treatments have been tried and in the context of a broader multidisciplinary plan. Evidence suggests that opioids can reduce pain in the short term (often by about 30% compared with placebo over 12–16 weeks), but long‑term benefits for pain, function, and quality of life are modest and often outweighed by risks.[1][4]
TYPICAL VS ATYPICAL OPIOIDS: HOW THEY DIFFER
TYPICAL (CONVENTIONAL) OPIOIDS
“Typical” or conventional opioids (e.g. morphine, oxycodone, hydromorphone, fentanyl) primarily work as agonists at the mu‑opioid receptor in the brain and spinal cord. By activating these receptors, they dampen pain signalling, but also slow gut motility, depress breathing, and can produce euphoria, tolerance, dependence, and addiction. Most traditional opioids have no major additional non‑opioid mechanisms, so their benefit–risk profile is dominated by mu‑opioid receptor effects.[2][7][4]
ATYPICAL OPIOIDS
“Atypical” opioids (often including tramadol, tapentadol, and low‑dose transdermal buprenorphine) combine mu‑opioid receptor activity with other mechanisms such as monoamine (noradrenaline/serotonin) reuptake inhibition or partial agonism.[8][7][9]
Tramadol: Has weak mu‑opioid activity via its active metabolite plus inhibition of noradrenaline and serotonin reuptake, enhancing descending pain‑inhibitory pathways. This mixed mechanism may reduce some typical opioid harms at low to moderate doses, but tramadol also carries unique risks such as serotonin syndrome and seizures, particularly with certain antidepressants or high doses.[7][8]
Tapentadol: Acts as a mu‑opioid agonist and potent noradrenaline reuptake inhibitor, with lower receptor affinity than morphine but synergistic analgesia across nociceptive and neuropathic pain states. Clinical studies suggest tapentadol offers similar pain relief to traditional strong opioids with improved gastrointestinal tolerability and a lower rate of serious adverse events and misuse than some conventional opioids.[9][8]
Buprenorphine: A partial mu‑agonist and kappa‑antagonist with a “ceiling” effect on respiration at therapeutic doses, which may confer a safer profile for transdermal use in chronic pain, though high‑dose sublingual formulations used in addiction treatment can behave more like conventional opioids.[8][7]
Atypical opioids are sometimes preferred when an opioid is needed for chronic pain because they may provide adequate analgesia with a somewhat lower risk of typical opioid harms, especially at carefully selected doses and formulations. However, they remain opioids and can still cause dependence, withdrawal, endocrine disruption, and other serious side effects.[3][2][7][9][8]
COMMON AND SERIOUS OPIOID‑RELATED ADVERSE EFFECTS
Long‑term opioid therapy can affect many organ systems, including gastrointestinal, endocrine, immune, musculoskeletal, cardiovascular, respiratory, and central nervous systems. The risk of harm generally increases with higher daily doses, longer duration of use, and combinations with sedatives (e.g. benzodiazepines) or alcohol.[2][3][1]
GASTROINTESTINAL EFFECTS (INCLUDING CONSTIPATION AND NAUSEA)
Constipation is one of the most frequent opioid side effects, caused by mu‑receptor activation in the gut that slows motility and increases fluid absorption. It can lead to bloating, abdominal pain, haemorrhoids, and in severe cases bowel obstruction, often requiring regular laxatives or peripherally acting opioid antagonists.[3][2]
Nausea and vomiting are common when opioids are started or doses increased, due to stimulation of the chemoreceptor trigger zone and delayed gastric emptying. These symptoms often improve over time but may limit tolerability in some patients.[2][3]
RESPIRATORY DEPRESSION AND OVERDOSE
Opioids suppress the brainstem respiratory centres, reducing breathing rate and responsiveness to carbon dioxide. At high doses, or when combined with other sedatives or alcohol, this can lead to life‑threatening respiratory depression and fatal overdose, a central driver of the opioid mortality crisis. Higher prescribed daily doses are consistently associated with increased overdose risk, even in patients using opioids as directed.[6][1][2]
CENTRAL NERVOUS SYSTEM AND COGNITIVE EFFECTS
Sedation, drowsiness, impaired concentration, and slowed reaction times are common, especially early in therapy or after dose changes. Long‑term use has been associated with increased risk of falls, fractures (particularly in older adults), and possible cognitive impairment, although data are still evolving. Opioids can also contribute to mood changes, including depression or emotional blunting, complicating the relationship between pain and mental health.[3][2]
OPIOID‑INDUCED HYPERALGESIA (OIH)
Opioid‑induced hyperalgesia is a paradoxical phenomenon where ongoing opioid exposure makes the nervous system more sensitive to pain, so that patients may experience increased or more diffuse pain despite dose escalation. Proposed mechanisms include changes in spinal cord processing, activation of pronociceptive pathways (e.g. via N‑methyl‑D‑aspartate receptors), and neuroinflammatory responses.[2][3]
Clinically, OIH may present as:
Worsening or spreading pain without clear new pathology, particularly at higher opioid doses.[3][2]
Limited or short‑lived benefit from dose increases, sometimes with improvement when the opioid dose is reduced or the medication is rotated.[2][3]
Recognition of OIH supports cautious dosing, avoidance of unnecessary escalation, and consideration of dose reduction, opioid rotation, or non‑opioid strategies when pain paradoxically worsens on long‑term therapy.[3][2]
OPIOID‑INDUCED ANDROGEN DEFICIENCY AND OTHER ENDOCRINE EFFECTS
Chronic opioid use can disrupt the hypothalamic–pituitary–gonadal and hypothalamic–pituitary–adrenal axes, leading to opioid‑induced androgen deficiency (OPIAD) and other hormonal problems.[10][2][3]
In men, reduced gonadotropin‑releasing hormone and downstream luteinising hormone and testosterone can cause low libido, erectile dysfunction, fatigue, reduced muscle mass, infertility, and increased risk of osteoporosis and fractures.[10][2][3]
In women, opioids can lower oestrogen, alter follicle‑stimulating hormone and prolactin, and lead to menstrual irregularities, reduced fertility, galactorrhoea, and bone loss.[10][2][3]
Symptoms are often subtle and may be misattributed to depression, ageing, or chronic illness, so OPIAD is under‑recognised. Some studies suggest that hypogonadism may itself increase pain sensitivity and worsen pain control, creating a feedback loop. Hormone levels often improve after dose reduction or discontinuation, and in selected cases hormone replacement may be considered after specialist review.[10][2][3]
IMMUNE, MUSCULOSKELETAL, AND OTHER SYSTEMIC EFFECTS
IMMUNE SYSTEM AND INFECTION RISK
Opioids can modulate both innate and adaptive immune responses, with evidence of immunosuppressive effects in long‑term use. Observational studies have linked chronic opioid therapy to increased risk of infections such as pneumonia, particularly in older adults and those with comorbidities. These immune effects may also influence cancer progression and wound healing, although findings are mixed and still under investigation.[2][3]
BONE, MUSCLE, AND CARDIOVASCULAR EFFECTS
Long‑term opioids, partly through endocrine changes and sedation, are associated with:
Reduced bone density and increased fracture risk, especially in older adults.[3][2]
Decreased muscle mass and physical conditioning, contributing to weakness and falls.[3]
Possible increased risk of cardiovascular events such as myocardial infarction or heart failure in some cohorts, though causal pathways are not fully understood.[2][3]
OTHER NOTABLE RISKS
Chronic opioid therapy is linked with sleep‑disordered breathing (including central sleep apnoea), weight changes, and in some individuals, development of opioid use disorder (addiction), characterised by loss of control, compulsive use, and continued use despite harm. Risk is higher in those with personal or family histories of substance use or certain psychiatric conditions.[1][2][3]
WEIGHING BENEFITS AND RISKS IN CHRONIC PAIN
For chronic non‑cancer pain, long‑term opioid therapy should be considered only after careful evaluation of potential benefits and harms and usually after first‑line non‑opioid options (physical therapies, psychological approaches, non‑opioid medicines) have been explored. When opioids are used, best practice includes:[4][1]
Clear goals focused on function and quality of life, not just pain scores.[4][1]
The lowest effective dose, regular review, and plans for tapering if benefits are limited or harms emerge.[1][2]
Screening for mental health conditions and substance use and integrating non‑pharmacological treatments within a biopsychosocial pain management plan.[4][1][2]
Understanding the history, pharmacology, and side‑effect profile of both typical and atypical opioids allows patients and clinicians to use these powerful medicines more safely, and to prioritise treatments that improve long‑term function and wellbeing with the least possible risk.[8][1][2][3]
